GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+12.02%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$303M
AUM Growth
+$303M
(-5.2%)
Cap. Flow
-$21.4M
Cap. Flow
% of AUM
-7.06%
Top 10 Holdings %
Top 10 Hldgs %
43.19%
Holding
69
New
16
Increased
8
Reduced
15
Closed
10
Top Buys
| 1 |
ALLK
Allakos
ALLK
|
$9M |
| 2 |
GH Research
GHRS
|
$8.82M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
$6.73M |
| 4 |
Leap Therapeutics
LPTX
|
$6.62M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$6.59M |
Top Sells
| 1 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$12.1M |
| 2 |
Biogen
BIIB
|
$11.3M |
| 3 |
RAPT Therapeutics
RAPT
|
$9.94M |
| 4 |
Fate Therapeutics
FATE
|
$8M |
| 5 |
TG Therapeutics
TGTX
|
$6.98M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SRRA
26
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $4.38M | 1.28% | 200,000 | – | – |
|
27
Zentalis Pharmaceuticals
ZNTL
$122M
| $4.33M | 1.27% | +65,000 | New | +$4.33M |
|
|
STSA
28
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $4.21M | 1.23% | 904,225 | – | – |
|
|
BCYC
29
Bicycle Therapeutics
BCYC
$511M
| $4.16M | 1.22% | 100,000 -100,000 | -50% | -$4.16M |
|
30
Gyre Therapeutics
GYRE
$703M
| $4.11M | 1.2% | 1,000,000 | – | – |
|
|
VRNA
31
Verona Pharma
VRNA
$9.16B
| $4.11M | 1.2% | 750,000 -250,000 | -25% | -$1.37M |
|
|
TCRR
32
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $4.06M | 1.19% | +477,323 | New | +$4.06M |
|
33
Vaxcyte
PCVX
$4B
| $4.06M | 1.19% | 160,000 +15,000 | +10% | +$381K |
|
34
Allogene Therapeutics
ALLO
$251M
| $3.86M | 1.13% | 150,000 -125,000 | -45% | -$3.21M |
|
35
Tarsus Pharmaceuticals
TARS
$2.47B
| $3.66M | 1.07% | 170,000 | – | – |
|
|
NMTR
36
DELISTED
9 Meters Biopharma, Inc. Common Stock
NMTR
| $3.58M | 1.05% | +2,750,000 | New | +$3.58M |
|
37
Crinetics Pharmaceuticals
CRNX
$2.92B
| $3.16M | 0.92% | 150,000 -93,309 | -38% | -$1.96M |
|
|
CMPS
38
Compass Pathways
CMPS
$424M
| $2.99M | 0.87% | +100,000 | New | +$2.99M |
|
|
39
Fate Therapeutics
FATE
$120M
| $2.96M | 0.87% | 50,000 -135,000 | -73% | -$8M |
|
40
Harmony Biosciences
HRMY
$2.12B
| $2.88M | 0.84% | 75,000 -50,000 | -40% | -$1.92M |
|
41
Amicus Therapeutics
FOLD
$2.34B
| $2.53M | 0.74% | 265,000 | – | – |
|
|
BLU
42
DELISTED
BELLUS Health Inc.
BLU
| $2.46M | 0.72% | +400,000 | New | +$2.46M |
|
43
Immunic
IMUX
$80.9M
| $2.35M | 0.69% | 265,000 | – | – |
|
44
Larimar Therapeutics
LRMR
$310M
| $2.31M | 0.67% | 200,000 +100,000 | +100% | +$1.15M |
|
45
Moderna
MRNA
$9.37B
| $2.04M | 0.6% | 5,300 +1,300 | +33% | +$500K |
|
46
Alector
ALEC
$238M
| $1.83M | 0.53% | +80,000 | New | +$1.83M |
|
47
Merus
MRUS
$4.98B
| $1.65M | 0.48% | 75,000 | – | – |
|
48
Fulcrum Therapeutics
FULC
$351M
| $1.41M | 0.41% | +50,000 | New | +$1.41M |
|
|
CMRX
49
DELISTED
Chimerix, Inc.
CMRX
| $1.24M | 0.36% | 200,000 | – | – |
|
50
Cabaletta Bio
CABA
$133M
| $1.22M | 0.36% | +100,000 | New | +$1.22M |
|